

Amyris Receives GRAS Notification from FDA for its New, Sugarcane-Derived, Zero Calorie Sweetener

EMERYVILLE, Calif., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, announced today that it has received a successful GRAS notification from the US Food and Drug Administration (FDA) for its zero calorie sweetener. With this notification, the FDA has accepted the unanimous conclusion of a panel of food-safety experts, we announced on August 30, 2018, that Amyris's zero calorie sweetener made from sugarcane is safe for use as a sweetener. The sweetener has the highest level of purity available today, the best taste of any alternative sweetener, and is made from a sustainable production process using fermentation.

"We are very pleased with the FDA GRAS acceptance of our zero calorie sweetener from sugarcane. We are making very good progress with sales and customers, and are developing a significant pipeline to advance and support our growth. The combination of our offer and product taste performance is unmatched in the industry and we believe this will lead to market leadership for our sweetener business. We continue to make great inroads overall and have strong momentum into the final weeks of the year," said John Melo, Amyris President and CEO.

About Amyris

Amyris is the integrated renewable products company that is enabling the world's leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise™ products and services across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. More information about the company is available at www.amyris.com.

Forward-Looking Statements

This release contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events, such as the expected commercialization of Amyris's new sweetener product, including the anticipated timing and cost thereof. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to Amyris's liquidity and ability to fund operating and capital expenses, potential delays or failures in development, production and commercialization of products, risks related to Amyris's reliance on third parties, and other risks detailed from time to time in filings Amyris makes with the Securities and Exchange Commission, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Amyris disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events, or otherwise.

Amyris, the Amyris logo and No Compromise are trademarks or registered trademarks of Amyris, Inc. in the U.S. and/or other countries.

Contact:

Peter DeNardo
Director, Investor Relations and Corporate Communications
Amyris, Inc.
+1 (510) 740-7481
investor@amyris.com

<https://investors.amyris.com/2018-12-12-Amyris-Receives-GRAS-Notification-from-FDA-for-its-New-Sugarcane-Derived-Zero-Calorie-Sweetener>